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SUMMARY
Purpose: Therapeutic hypothermia reduces mor-
tality and neurologic impairment in neonates with
hypoxic–ischemic encephalopathy. Topiramate
exerts a neuroprotective effect in asphyxiated
neonatal animal models. However, no studies have
investigated the association of hypothermia and
topiramate, because topiramate pharmacokinetics
during hypothermia and the optimal administration
schedule are unknown. The influence of hypothermia
on topiramate pharmacokinetics was evaluated in
asphyxiated neonates treated with prolonged
whole-body hypothermia and topiramate.
Methods: Thirteen term newborns were treated
with mild or deep whole body hypothermia for
72 h; all received oral topiramate, 5 mg/kg once a
day for the first 3 days of life, and seven had con-
comitant phenobarbital treatment. Topiramate
concentrations were measured on serial dried
blood spots.
Results: Topiramate concentrations were within
the reference range in 11 of 13 newborns, whereas
concentrations exceeded the upper limit in 2 of 13,
both newborns on deep hypothermia. Topiramate
concentrations reached a virtual steady state in
nine newborns, for whom pharmacokinetic
parameters were calculated. Values of topiramate
maximal and minimal concentration, half-life,
average concentration, and area under the
time—concentration curve resulted in consider-
ably higher values than those reported in normo-
thermic infants. With respect to normothermic
infants, time of maximal concentration was mildly
delayed and apparent total body clearance was
lower, suggesting slower absorption and elimina-
tion. Pharmacokinetic parameters did not differ
significantly between infants on deep versus mild
hypothermia and in those on topiramate mono-
therapy versus add-on phenobarbital.
Conclusion: Most neonates on prolonged hypo-
thermia treated with topiramate 5 mg/kg once a
day exhibited drug concentrations within the ref-
erence range for the entire treatment duration.
KEY WORDS: Newborn, Asphyxia, Neuroprotec-
tion, Pharmacokinetics.
Recent trials have demonstrated that mild hypothermia
(MH), started within 6 h after birth and protracted for
48–72 h, can significantly improve survival and reduce
neurologic impairment in neonates with hypoxic—ische-
mic encephalopathy (HIE) (Eicher et al., 2005; Gluckman
et al., 2005; Shankaran et al., 2005). MH can be obtained
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by selective head or whole-body cooling (rectal or esopha-
geal temperature 33–34C). A preliminary study showed
also that deep hypothermia (DH) (temperature 30–33C)
is similarly safe and neuroprotective (Compagnoni et al.,
2008). Recently, an interim advisory statement proposed
support for the introduction of therapeutic hypothermia in
the recommendations of the International Liaison Com-
mittee on Resuscitation (Hoehn et al., 2008).
It is not currently known whether neuroprotective
drugs can further improve the beneficial effects of hypo-
thermia. Topiramate (TPM) is an antiepileptic drug with
multiple mechanisms of action, including glutamate-
receptor inhibition (Shank et al., 2000; Guerrini &
Parmeggiani, 2006). TPM demonstrated neuroprotective
properties in vitro and in animal models in vivo (Ange-
hagen et al., 2005; Sfaello et al., 2005; Noh et al., 2006)
and was recently proposed as an innovative neuroprotec-
tive therapy for ischemic stroke (Yang et al., 1998; Lee
et al., 2000; Edmonds et al., 2001; Follett et al., 2004;
Liu et al., 2004; Schubert et al., 2005; Costa et al., 2006;
Noh et al., 2006) and neonatal hypoxic–ischemic cere-
bral injury (Choi & Kim, 2007). However, the associa-
tion of hypothermia and TPM for the treatment of HIE
has not been investigated.
Hypothermia affects the pharmacokinetics of several
drugs (Tortorici et al., 2007). In order to plan future
trials designed to evaluate the possible neuroprotec-
tive effects of combined topiramate and hypothermia,
we studied the pharmacokinetics of TPM in newborns
treated with hypothermia. Thirteen neonates with HIE
were treated with hypothermia and oral TPM admin-
istrations, with serial determinations of plasma TPM
concentrations.
Patients and Methods
From January to August 2008, 13 full-term newborns
with HIE were enrolled in two Italian neonatal intensive
care units (NICUs), (A. Meyer University Children’s
Hospital, Florence and Carlo Poma Hospital, Mantua).
Infants were treated with whole-body DH or MH, started
within 6 h after birth and maintained for 72 h if the two
following criteria were fulfilled: (1) Gestational age
‡36 weeks and birth weight ‡1,800 g with at least one of
the following: (a) Apgar score £5 at 10 min; (b) persisting
need for resuscitation, including endotracheal intubation
or mask ventilation for more than 10 min after birth;
(c) acidosis (pH £7.0 and/or base deficit ‡)16 mmol/L in
umbilical cord blood or arterial, venous, or capillary
blood) within 60 min from birth; (2) moderate to severe
encephalopathy consisting of altered state of conscious-
ness (irritability, lethargy, stupor, or coma) and ‡1 of
the following signs: (a) hypotonia, (b) abnormal ref-
lexes including oculomotor or pupillary abnormalities,
(c) absent or weak suctioning, (d) clinical seizures.
Exclusion criteria were congenital abnormalities, viral
infections, or encephalopathy different from HIE. Outborn
patients were initially cooled to 35C at the birth hospital,
avoiding heating and using ice packs during the transfer to
neonatal intensive care unit (NICU). In NICUs, infants
allocated to treatment with DH were cooled to rectal or
esophageal temperature of 30–33C, whereas newborns
allocated to treatment with MH were cooled to 33–34C.
In one center (Mantua) hypothermia was induced by
applying ice packs to head and body. Rectal temperature
was continuously monitored by a probe connected to car-
diomonitor (Viridia 24C, Hewlett-Packard Company,
Palo Alto, CA, U.S.A. or Infinity Delta, Drger Medical
System, Telford, PA, U.S.A.) for simultaneous measure-
ment with respiratory rate, heart rate, blood pressure, and
oxygen saturation. In the other center (Florence) hypo-
thermia was obtained by a cooling blanket (Blanketrol III,
Hyper-Hypothermia System; Cincinnati Sub-Zero,
Cincinnati, OH, U.S.A.). An esophageal probe was
inserted, and esophageal temperature was lowered to
33.5C by the blanket’s servomechanism. Skin tempera-
ture was monitored on the abdominal wall with a skin
probe by the radiant warmer thermal sensor or a tempera-
ture-monitoring unit (Mon-a-therm; Mallinckrodt
Medical, St Louis, MO, U.S.A.). After 72 h of hypo-
thermia, newborns were gradually rewarmed to 36.5–37
C over the following 6–12 h (0.5C/h). In newborns
treated with a cooling blanket, the automatic control
setpoint was increased by 0.5C per hour.
Vital signs were monitored continuously and daily
determinations of liver–renal function tests, coagulation
tests, and blood cell count were performed. Hematocrit
was determined using an automated Coulter counter
(Beckman-Coulter ACt.8, High Wycombe, United
Kingdom). Blood-gas measurements were corrected for
body temperature. Hypotension, defined as mean arterial
blood pressure <40 mm Hg, was treated with single or
repeated normal saline boluses, and in the case of
persisting hypotension, dopamine, dobutamine, or nor-
epinephrine was administered. Seizures were treated
with phenobarbital (PB) (loading dose 20 mg/kg, fol-
lowed by maintenance dose, 2.5 mg/kg every 12 h). A
cerebral magnetic resonance (MR) scan was performed
within the first week of life. The study protocol was
approved by the research ethics committee of Carlo
Poma Hospital, Mantua, and A. Meyer Hospital, Flor-
ence, Italy. Written informed consent for participation
and publication was obtained from both parents of
involved newborns.
TPM (Topamax; Janssen-Cilag, Cologno Monzese,
Milan, Italy) was administered by orogastric tube as
enteric-coated granules mixed with water, at the dosage
of 5 mg/kg/day, starting from the beginning of hypo-
thermia, once a day for the first 3 days of life for a
total amount of three doses for each neonate. This sche-
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dule was arbitrarily chosen, assuming that hypothermia
would not prevent TPM absorption, but rather reduce
TPM clearance.
Study design
TPM concentrations were measured on dried blood
spots (DBS) by liquid chromatography tandem mass spec-
trometry (LC-MS/MS assay), as described previously (la
Marca et al., 2008). Values were then corrected by hemat-
ocrit, obtaining plasma values. Each value from DBS was
divided by (100)hematocrit)/100.
Plasma TPM concentrations were evaluated for the first
nine patients (four with MH and five with DH), after 48 h
of hypothermia, before the administration of the third dose
of TPM (T48 h) and at T48.5, T49, T49.5, T50, T52, T54, T56,
T60, T64, T68, and T72. Three newborns were co-treated
with PB. To obtain a more detailed TPM profile, in the
following four patients (all treated with MH), plasma
TPM concentrations were measured at the beginning of
hypothermia, before the first dose of TPM (T0), and at
T0.5, T1, T1.5, T2, T4, T6, T8, T12, T16, T20, and T24 (before
the second dose), at T26, T30, T34, T40, and T48 (before the
third dose), and at T48.5, T49, T49.5, T50, T52, T54, T56, T60,
T64, T68, and T72. All of these four newborns were also on
PB.
TPM concentration assessment
In adult patients with normal renal function, oral TPM
reaches steady state in about 4 days (Tidwell & Swims,
2003). However, our patients were treated with hypother-
mia and TPM for only 72 h. Therefore, TPM was consid-
ered to have reached ‘‘virtual’’ steady state if its
concentrations at T72 were within the concentration at
T48 € 10%. For newborns who reached TPM virtual
steady state, the following pharmacokinetic parameters
were derived by a noncompartmental method (WinNonlin
Prof, version 4.0.1; Pharsight, Mountain View, CA,
U.S.A.): maximal plasma concentration (Cmax), minimal
plasma concentration (Cmin), time of peak concentrations
(Tmax), area under plasma concentration–time curve from
0–24 h (AUC0–24) which was calculated using the linear
trapezoidal rule for TPM. Half-life (T1/2) was derived
from the slope b of the log-linear phase. The average
plasma concentration (Cavg) during the 24-h dosing
interval was calculated from the quotient AUC0–24/24.
Apparent oral clearance (CL/F) was calculated according
to the following equation: CL/F (ml/kg/h) = TPM daily
dose (mg/kg)/[AUC0–24(mg/L/h)] · 1,000.
Statistical analysis
The trial was designed as a pilot study with limited
recruitment of neonates. Means and standard deviations
of TPM concentrations were calculated for all
newborns, whereas pharmacokinetic parameters were
calculated for newborns who reached the steady state.
Data were then compared between newborns treated
with MH or DH and between newborns with or without
PB co-treatment. Differences in variables between
the groups were first analyzed with analysis of variance
(ANOVA) (threshold p = 0.05) and, when a signifi-
cant difference was found in a variable, groups were
compared using the Student t-test (total threshold
p = 0.05).
Results
Thirteen newborns, 3 female and 10 male, were
enrolled (Table 1). Mean age at inclusion was 4.0 € 1.7 h.
Mean temperature of outborn newborns at arrival in
NICUs was 34.8 € 0.5C. Five newborns were treated
with DH (temperature range 29.7–33.7C) and eight with
MH (temperature range 32.7–34.5C) (Fig. 1). TPM was
administered at 4.3 € 1.3 h. Seven newborns were treated
with PB for seizures starting at 4.5 € 1.0 h.
TPM plasma concentrations, obtained by converting
measurements on DBS corrected with actual hemato-
crit, were recorded in all newborns and plotted in a
manner distinguishing between newborns in DH or MH
(Fig. 2), and between newborns receiving PB or not
(Fig. 3). Newborns treated with MH and cotreated with
PB showed lower TPM concentrations, although no
statistically significant differences were observed. The
coefficient of variability (CV) of TPM values was sig-
nificantly higher in the DH group than in the MH
group (p < 0.005).
Among the 13 newborns, 9 (69.2%) reached the vir-
tual steady state; 3 were treated with DH and 6 with
MH, 4 received PB and TPM, whereas 5 were treated
with TPM only. Pharmacokinetic parameters in DH or
MH treated newborns (Table 2) did not show signifi-
cant differences, although lower AUC0–24 (p 0.096),
lower Cavg (p 0.096), and higher T1/2 (p 0.080), in DH
group were observed. Newborns who were co-treated
with PB exhibited significantly lower Cmin than those
on TPM alone (p 0.032), and lower concentrations of
Cmax (p 0.060), AUC0–24 (p 0.068), Cavg (p 0.068), T1/2
(p 0.113), and higher CL/F (p 0.078) (Table 2). Param-
eter differences did not reach statistical significance,
probably because of the small sample size. The subset
of newborns who did not reach the steady state showed
at T72 TPM concentrations that were 33.6% (€4.6%)
higher than that measured at T48.
No adverse effects attributable to TPM were identified,
and none of the patients were prematurely discontinued
because of limiting adverse events during association
therapy of TPM and hypothermia. Twelve of 13 treated
infants survived. A cerebral MR scan was performed at
5.3 € 1.8 days and results were normal in six newborns
(46.2%). Two newborns showed isolated white matter
lesions; one exhibited isolated basal ganglia lesions; three
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showed combined basal ganglia, thalamic and cortical
injuries; and a more diffuse pattern of brain injury (basal
ganglia, thalami, cortex, and white matter) was observed
in one infant.
Discussion
TPM has demonstrated neuroprotective properties in
neuronal cultures exposed to oxygen-glucose deprivation
(Noh et al., 2006) or excitotoxic glutamate or kainate con-
centrations (Angehagen et al., 2005), and in adult rodent
models of transient global cerebral ischemia (Yang et al.,
1998; Lee et al., 2000; Edmonds et al., 2001). Intravenous,
intraperitoneal, and oral TPM, alone or combined with
hypothermia, also reduced hypoxic–ischemic cerebral
injury in newborn animals in a dose-dependent manner,
with a neuroprotective dose ranging from 5–200 mg/kg,
usually in single administration (Lee et al., 2000;
Edmonds et al., 2001; Liu et al., 2004; Schubert et al.,
2005; Noh et al., 2006). TPM was also demonstrated to
exert neuroprotective effects against periventricular
leukomalacia (Follett et al., 2004). TPM neuroprotective
properties have been attributed mainly to glutamate
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate
(AMPA)-kainate receptor inhibition (Follett et al., 2004;
Kaminski et al., 2004; Koh et al., 2004; Angehagen et al.,
2005; Sfaello et al., 2005), but also to blockade of Na+
channels (Zona et al., 1997), high voltage-activated
calcium currents (Costa et al., 2006), carbonic anhydrase
isoenzymes (Dodgson et al., 2000), and mitochondrial
permeability transition pore (MPTP) (Kudin et al., 2004).
The neuroprotective mechanism of combined hypother-
mia and TPM in HIE is still uncertain, but might rely on
additive or synergistic action of TPM on hypothermia
effects, such as glutamate reuptake preservation and inhi-
bition of nitric oxide synthase, oxidative stress, and apop-
tosis (Edwards et al., 1995; Thoresen et al., 1997; Liu
et al., 2004).
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Figure 1.
Temperature profile of newborns treated with deep or
mild hypothermia.
Epilepsia ILAE
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Although perinatal HIE is the single most important
cause of serious brain injury in newborns, to date no clini-
cal study has been published to prove TPM efficacy and
evaluate combined TPM and hypothermia treatment in
newborns with HIE.
TPM exhibits high affinity/saturable low-capacity bind-
ing to erythrocytes (Patsalos et al., 2008), and this pecu-
liarity contributes to a different pharmacokinetics of TPM
when determined in plasma or in whole blood (Shank
et al., 2005). Considering that hematocrit influences sig-
nificantly the plasma/whole-blood distribution of TPM
(Gidal & Lensmeyer, 1999), conversion from DBS to
plasma values was made according to hematocrit. TPM
determination by LC-MS/MS on DBS, converted to
plasma concentration, provides values comparable to
those obtained on heparinized plasma (la Marca et al.,
2008).
However, TPM pharmacokinetic determinations pre-
sented some limitations. First, the steady state was
approximated. Second, in neonates, peculiarity of gastro-
intestinal pH, emptying time, enzymatic activities,
splanchnic blood flow pattern, and increased total body
Figure 3.
Plasma TPM concentrations in
newborns co-treated with PB or
with TPM alone. Gray area
represents the reference range.
Epilepsia ILAE
Figure 2.
Plasma TPM concentrations in
newborns treated with deep or
mild hypothermia. Gray area
represents the reference range.
Epilepsia ILAE
Table 2. Mean ± SD topiramate pharmacokinetic profiles of newborns who reached the virtual
steady state. Data are plotted that distinguish between newborns in DH or MH and between
newborns receiving PB or not
All newborns
(n = 9)
Newborns with
DH (n = 3)
Newborns with
MH (n = 6) p-value
Newborns with
PB (n = 4)
Newborns without
PB (n = 5) p-value
Cmax, mg/L, mean ± SD 17.96 ± 4.2 17.87 ± 6.4 18.71 ± 3.2 0.219 15.38 ± 5.3 19.87 ± 1.9 0.060
Cmin, mg/L, mean ± SD 10.35 ± 2.5 10.54 ± 3.2 10.77 ± 1.9 0.199 8.70 ± 2.9 11.67 ± 0.9 0.032
Tmax, h, mean ± SD 3.80 ± 2.2 4.00 ± 1.1 4.08 ± 2.7 0.333 3.13 ± 2.4 4.40 ± 2.2 0.216
AUC0–24, mg/L/h, mean ± SD 343.2 ± 72.2 318.1 ± 101.6 366.2 ± 48.1 0.096 302.4 ± 89.7 375.8 ± 37.4 0.068
Cavg, mg/L, mean ± SD 14.29 ± 3.0 13.25 ± 4.2 15.26 ± 2.0 0.096 12.60 ± 3.7 15.66 ± 1.6 0.068
T1/2, h, mean ± SD 35.58 ± 19.3 48.82 ± 4.6 29.03 ± 23.8 0.080 26.46 ± 17.7 42.88 ± 19.1 0.113
CL/F, ml/kg/h, mean ± SD 15.42 ± 4.6 15.72 ± 7.3 13.87 ± 1.9 0.084 17.92 ± 6.2 13.42 ± 1.4 0.078
DH, deep hypothermia; MH, mild hypothermia; PB, phenobarbital; Cmax, maximal plasma concentration; Cmin, minimal plasma
concentration; Tmax, time of peak concentrations; AUC0-24, area under plasma concentration-time curve from 0 to 24 h; Cavg,
average plasma concentration; T1/2, half-life; CL/F, apparent oral clearance.
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water/fat ratios (Kearns et al., 2003) considerably influ-
ence drug absorption and distribution, whereas physio-
logically poor renal function can influence TPM clearance
(Morselli et al., 1980). Third, a small amount of TPM is
metabolized by hydrolysis, hydroxylation, and glucuroni-
dation, which are markedly enhanced by enzyme-inducing
antiepileptic drugs (AEDs) (Perucca & Bialer, 1996),
although drug-metabolizing enzymes show poor activity
in newborns (Perucca, 2006).
Available data on TPM pharmacokinetics in normother-
mic neonates are limited to newborns of mothers treated
with TPM and carbamazepine, in whom TPM half-life
was approximately 24 h (Ohman et al., 2002), as in
healthy adults (Johannessen, 1997). In infants and children
TPM Cmax appears directly related to dose, suggesting
proper oral bioavailability (Glauser et al., 1999; Mikaeloff
et al., 2004). Concomitant treatment with enzyme-induc-
ing AEDs increases TPM clearance, with significantly
lower Cmax, AUC, and half-life (Glauser et al., 1999;
Mikaeloff et al., 2004).
Our pilot trial demonstrates that an oral TPM schedule
of 5 mg/kg, once a day, determined in most newborns
plasma concentrations within the reference range of
5–20 mg/L (Johannessen & Tomson, 2006; Patsalos et al.,
2008), indicating that oral TPM absorption is maintained
during hypothermia. This schedule was chosen arbitrarily
with the purpose of rapidly achieving plasma levels within
the reference range for a short period of time, in contrast
to seizure treatment schedules that aim to gradually reach
the effective dosage. Hypothesizing that hypothermia
would determine higher TPM plasma levels, we chose the
lowest dosage among maintenance therapy schedules in
infants (Glauser et al., 1999; Rosenfeld et al., 1999;
Mikaeloff et al., 2004; Battino et al., 2005). Assuming a
longer TPM half-life during hypothermia we chose a
single daily administration.
Plasma TPM concentration during hypothermia
appeared definitely higher than reported in normothermic
infants treated with analog dosages (Mikaeloff et al.,
2004; Battino et al., 2005). Newborns treated with DH
showed higher TPM concentrations between 48 and 72 h
than newborns treated with MH, with higher concentration
variability, probably because of more irregular TPM
absorption and elimination. TPM values exceeded 20 mg/
L in only one newborn in MH, whereas values exceeded
25 mg/L in three of five newborns in DH. TPM plasma
concentrations did not differ between newborns receiving
TPM and PB or TPM alone, suggesting that the main
cause of higher variability in the DH group was the depth
of hypothermia.
Nine newborns who reached TPM virtual steady state
exhibited definitely higher Cmax, Cmin, AUC0–24, Cavg,
and T1/2 values than reported in normothermic infants
treated with the same or higher dosage (Glauser et al.,
1999; Rosenfeld et al., 1999; Mikaeloff et al., 2004), sug-
gesting slower TPM elimination during hypothermia.
Hypothermia significantly reduces the clearance of sev-
eral drugs, including sedatives, anesthetics, and anticon-
vulsants (Tortorici et al., 2007). Morphine was even
reported to reach potentially toxic levels in asphyxiated
newborns under hypothermia (Rka et al., 2008). Reduced
drug clearance during hypothermia is mainly attributable
to reduced activity of the cytochrome P450 enzymatic sys-
tem but also to reduced cardiac output and glomerular fil-
tration rate of drugs mainly excreted unchanged in urines
(Tortorici et al., 2007). Therefore, the reduced glomerular
filtration rate, probably in combination with a physiologic
immaturity of renal function during the first days of life
(Kearns et al., 2003), might explain the low TPM clear-
ance observed in our hypothermic population. We
observed delayed Tmax values with respect to normother-
mic infants (Glauser et al., 1999; Rosenfeld et al., 1999;
Mikaeloff et al., 2004), consistent with slower TPM
absorption under hypothermia. Finally, DH and PB come-
dication were associated with lower TPM concentrations
and higher CL/F. However, these findings were not signif-
icant, probably because TPM steady state was reached in
only a limited number of newborns. Larger trials are
needed to determine whether higher TPM dosages are nec-
essary in newborns under PB comedication.
In conclusion, this pilot trial identified TPM dosage that
can ensure plasma values within the reference range dur-
ing hypothermia. The optimal TPM schedule for neonates
under hypothermia as well as the neuroprotective effects
in HIE remain to be established.
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